Literature DB >> 23425072

Acidic deoxycholic acid and chenodeoxycholic acid induce interleukin-8 production through p38 mitogen-activated protein kinase and protein kinase A in a squamous epithelial model.

Jing Shan1, Tadayuki Oshima, Hirokazu Fukui, Jiro Watari, Hiroto Miwa.   

Abstract

BACKGROUND AND AIM: Immune-mediated mucosal inflammation characterized by the production of interleukin (IL)-8 is associated with the development of gastroesophageal reflux disease. The effects of bile acids, which are major components of reflux fluid, on the production of IL-8 and related mechanisms remain unclear. This study aimed to address these questions using an esophageal stratified squamous epithelial model.
METHODS: Normal human esophageal epithelial cells were seeded on the Transwell inserts and cultured with the air-liquid interface system to establish the model. Bile acids under different pH conditions were added to the apical compartment to examine their effects on IL-8 production and the underlying cellular signaling.
RESULTS: Conjugated bile acids under a neutral or acidic condition did not induce IL-8 production, and unconjugated bile acids, deoxycholic acid (DCA), and chenodeoxycholic acid (CDCA) all significantly induced IL-8 production, dose- and time-dependently, only under weakly acid conditions. Inhibition of p38 mitogen-activated protein kinase (p38 MAPK) and protein kinase A (PKA) attenuated the production of IL-8 induced by acidic DCA and CDCA. Inhibition of PKA did not block the bile acid-induced p38 MAPK activation.
CONCLUSIONS: Compared with conjugated bile acids, the unconjugated bile acids DCA and CDCA are more likely to induce IL-8 production in vivo, especially under weakly acid conditions. This process involves two independent signaling pathways, p38 MAPK and PKA.
© 2013 Journal of Gastroenterology and Hepatology Foundation and Wiley Publishing Asia Pty Ltd.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23425072     DOI: 10.1111/jgh.12139

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  6 in total

1.  Epithelial-derived nuclear IL-33 aggravates inflammation in the pathogenesis of reflux esophagitis.

Authors:  Jing Shan; Tadayuki Oshima; Taichiro Muto; Koubun Yasuda; Hirokazu Fukui; Jiro Watari; Kenji Nakanishi; Hiroto Miwa
Journal:  J Gastroenterol       Date:  2014-08-17       Impact factor: 7.527

2.  A weakly acidic solution containing deoxycholic acid induces esophageal epithelial apoptosis and impairs integrity in an in vivo perfusion rabbit model.

Authors:  Nicolas A Pardon; Maria Vicario; Hanne Vanheel; Tim Vanuytsel; Laurens J Ceulemans; Michael Vieth; Marcel Jimenez; Jan Tack; Ricard Farré
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2016-01-21       Impact factor: 4.052

3.  Interferon γ-Induced Nuclear Interleukin-33 Potentiates the Release of Esophageal Epithelial Derived Cytokines.

Authors:  Jing Shan; Tadayuki Oshima; Liping Wu; Hirokazu Fukui; Jiro Watari; Hiroto Miwa
Journal:  PLoS One       Date:  2016-03-17       Impact factor: 3.240

4.  Exploration of the Esophageal Mucosal Barrier in Non-Erosive Reflux Disease.

Authors:  Nicolaas F Rinsma; Ricard Farré; Fred J Troost; Montserrat Elizalde; Daniel Keszthelyi; Zsuzsanna Helyes; Ad A Masclee; José M Conchillo
Journal:  Int J Mol Sci       Date:  2017-05-19       Impact factor: 5.923

5.  Short-Term Symptomatic Relief in Gastroesophageal Reflux Disease: A Comparative Study of Esomeprazole and Vonoprazan.

Authors:  Kouichi Sakurai; Hiroko Suda; Satomi Fujie; Takayuki Takeichi; Ayako Okuda; Tetsuya Murao; Kiwamu Hasuda; Masahiro Hirano; Kiyoharu Ito; Katsuie Tsuruta; Masahiro Hattori
Journal:  Dig Dis Sci       Date:  2018-11-10       Impact factor: 3.199

6.  Deoxycholic acid induces gastric intestinal metaplasia by activating STAT3 signaling and disturbing gastric bile acids metabolism and microbiota.

Authors:  Duochen Jin; Keting Huang; Miao Xu; Hongjin Hua; Feng Ye; Jin Yan; Guoxin Zhang; Yun Wang
Journal:  Gut Microbes       Date:  2022 Jan-Dec
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.